Top 20 Blue Chip Stocks Based on Deep-Learning: Returns up to 25.00% in 14 Days

Top 20 Blue Chip Stocks

This forecast is part of the Top 20 Stocks Package, as one of I Know First’s systematic trading tools. The full package includes a daily prediction for a total of 40 stocks with bullish and bearish signals:

  • Top 20 stocks pick for the long position
  • Top 20 stocks pick for the short position


Package Name: Top 20 Stocks
Recommended Positions: Long
Forecast Length: 14 Days (12/08/2017 – 12/22/2017)
I Know First Average: 6.14%
Top 20 Blue Chip Stocks

I Know First’s State of the Art Algorithm accurately forecasted 14 out of 20 trades in this Top 20 Stocks Package for the 14 Days time period. The greatest return came from TEVA at 25.00%. VRX and UAA also performed well for this time horizon with returns of 22.23% and 16.72%, respectively. The package itself saw an overall return of 6.14%, providing investors with a 4.38% premium above the S&P 500’s return of 1.76% for the same time period.

Teva Pharmaceutical Industries Limited (TEVA) develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company’s Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The company’s Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders; Fentora/Effentora for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Zecuity, a prescription transdermal system for the acute treatment of migraine with or without aura in adults. This segment’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Granix, Trisenox, Synribo, Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim, and Trisenox products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, OTC/Rx, Zoely, Seasonique, and Ovaleap, as well as other products. Teva Pharmaceutical Industries Limited (TEVA) has collaboration arrangements with Takeda Pharmaceutical Company Limited, Procter & Gamble Company, Intel, and Regeneron Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.